| Sign In | Quick Order CART (0)
  • Cancer Research (White Paper)

    8 March 2016

    Cancer Research

    Cancer cells represent the manifestation of a breakdown in any number of normal cell states involving a wide range of cellular processes and cell types, thus the complexity of this disease cannot be understated. Mutations or changes anywhere from somatic DNA, through to active stem cells, as well as epigenetic changes, and environmental factors can all contribute to the resulting disease, and cancer research areas are just as diverse as these contributing factors. The range of reagents, kits and assays from Bioline support all aspects of cancer research, including oncogenes and genetic markers, epigenetic changes, as well as biomarkers and personalised medicine approaches.

    Cancer - a mixed bag of disease states
    Our bodies are composed of a broad range of cell types that grow, divide, and function in a controlled manner - interacting with other cells to form organised matrices, differentiating into specific types of cells where required, and breaking down when damaged or no longer needed. The processes that control normal cell activity are complex and multi-level, and mutations in any number of them can lead to cancer – the continual, unregulated proliferation of cells that grow, reproduce and eventually migrate throughout the body.

    There are over 200 different types of known cancers, classified based on the type of cell from which they arise, falling into three main groups:

    • Carcinomas – malignancies of epithelial cells, representing over 90% of known cancers and manifesting as abnormal growth of tissue (tumours).

    • Leukemias/Lymphomas – produced from blood-forming cells and cells of the immune system, accounting for roughly 8% of human malignancies, supressing normal blood cell production and immune system function.

    • Sarcomas – solid tumours of connective tissues such as muscle or bone, these cancers are relatively rare in humans.

    Further classification is based on the type of cell involved and the tissue of origin – for example erythroid leukemias are precursors of erythrocytes. The four most common cancers are breast, prostate, lung and colon, accounting for more than 50% of all cancer cases.

    Cancer – mutations within basic cellular processes
    The genes within a genome hold the blueprint for creation of the protein molecules that perform many of the important functions of a healthy cell. Mutations within this blueprint have the potential to affect protein production and resulting cellular function. Bioline offers an excellent range of end-point and Real Time PCR reagents and kits to support research into the genomics of cancer and cancer-related mutations. Usually a number of mutations are required before a cell exhibits cancerous properties, typically involving abnormalities in the mechanisms that control cell proliferation, differentiation and survival.

    Proliferation
    A primary hallmark of cancerous cells is their ability to sustain chronic cell proliferation – growing to high cell densities and larger cell sizes, with limited spatial regulation. Normal cells exhibit density-dependent growth and proliferation, controlled by complex pathways of growth-promotion and inhibitory signalling. There are a number of ways through which cancer cells can bypass normal proliferative mechanisms including producing their own growth-factor ligands, stimulating neighbour cells to produce various growth factors, or by altering cell surfaces to become hyper-responsive to growth factors. Research in this area looks at a number of different aspects of cell-growth mechanisms, such as mutations that lead to disruptions in the negative feedback mechanisms that reduce proliferative signalling, or those that aid in the evasion of growth suppressors, as well as somatic mutations that activate downstream pathways involved in cell proliferation.

    Apoptosis
    All normal cells are subject to a process called apoptosis, the programmed cell death process that occurs in response to the absence of growth factors or other environmental stimulations, or as a result of DNA damage. The ability to evade apoptotic processes is another hallmark of cancerous cells, increasing their lifespans and significantly contributing to tumour growth. Upstream regulators and downstream effector components contribute to the apoptotic machinery of the cell environment and consist of both extra- and intra-cellular signalling pathways. There are a number of ways through which tumour cells circumvent or limit apoptosis, such as increasing expression of antiapoptotic regulators, downregulating proaptotic factors, or through the total loss of tumour suppressor genes.

    Tissue Invasion and Metastasis
    Cell-cell interactions and the phenomenon of contact inhibition control the orderly way in which normal cells grow, migrate and adhere to each other to form a healthy cell matrix. In contrast, cancerous cells continue migration regardless of cell contact, growing in multi-layered and disorderly patterns. In addition, many malignant cells secrete proteases to digest the components of the extracellular matrix and enable invasion of adjacent tissue. Another hallmark of cancer cells is the ability to promote the formation of new blood vessels – angiogenesis – required to supply much needed oxygen and nutrients to the proliferating tumour. The activation of this angiogenic switch can be related to factors that either induce or oppose angiogenesis, and most likely a number of countervailing factors. The ability to metastasise, that is to migrate or spread to another part of the body not directly connected with the original tumour, involves a complex invasion-metastasis cascade that is still being understood, and includes mechanisms that both allow for physical dissemination from the primary tumour, as well as adaptation to the foreign tissue environment at the secondary destination.

    Cancer research – genetic predisposition through to personalized medicine
    Bioline offers reagents that support all areas of cancer research, from individual reagents and kits for PCR and Real Time PCR, through to fully optimised custom designed assays. Real Time PCR Assay panels of a full range of miRNA targets associated with cancer-related processes are also available to assist researchers in identifying appropriate targets for further study, and ISO13485 manufactured reagents provide the required quality for developing assays for personalised medicine approaches.

    Oncogene/tumour suppressor research
    Oncogenes can be defined as any gene or gene cluster, typically involved in an important cellular function such as differentiation, proliferation or apoptosis, which can turn a normal cell cancerous under specific circumstances. Since the completion of the Human Genome Project and the continued progression of deep sequencing approaches for a range of tumours and cancer types, there has been much hope that identification of key oncogenes would become evident, and once identified, ways in which to counter their activation could be devised. What has instead come to light is an unpredicted level of diversity both within and between cancers that have been sequenced thus far. Mutations in several hundred different genes have been identified as drivers of cancer, and while data is still being gathered, no clear candidates for subsequent treatment development have emerged thus far, so research efforts continue.

    Epigenetic cancer research
    The presence of a gene, or indeed a gene mutation, does not necessarily result in subsequent translation of an affected protein. Physiological or phenotypic variations can be observed in genetically identical cells that contain, for example, differences in DNA methylation or histone modifications, properties that alter the transcriptional potential of a cell. Epigenetic changes can occur as a result of environmental influences, they are heritable as well as reversible, and epigenetic changes contribute to carcinogenesis, thus studies in cancer epigenetics are thriving and this area holds promise for the development of cancer treatment options.

    Tumour microenvironment research
    The tumour, or cancer microenvironment is the cellular environment within which a tumour exists, comprised of immune cells, fibroblasts, blood vessel cells, as well as the proteins produced by these non-cancerous cells that support the growth of cancer cells. It is difficult to dissociate the microenvironment from traditionally defined cancer cells, however data suggests that dysfunction within the microenvironment is linked to carcinogenesis, thus understanding the pathophysiology of the microenvironment is a path towards development of chemopreventive agents. Research in this area attempts to understand the dynamic and reciprocal interactions between tumour cells and the cells that orchestrate their growth, metastatic properties or drug resistance progression.

    Cancer biomarkers and personalised medicine
    Biomarkers are biological molecules, such as proteins or nucleic acids, which are found in body fluids or tissues and can be used to assess the state of a biological process, or differentiate normal from disease state. A wide range of biomarkers for cancer have been identified across the full spectrum of cellular processes involved in the disease, and these biomarkers can be used to estimate risk towards developing disease, screen for active disease, determine disease prognoses, and both predict response to therapy and monitor therapeutic responses. There are many researchers committed to unravelling the immense complexity of biological and cellular information that has been collected thus far across the 200-odd diseases that are collectively known as cancer. Insights into this diversity and individual correlations within disease state form the foundation of biomarker development and subsequent personalised medicine. Today almost half of the cancer medicines and treatments in development are linked to small-molecules or novel biologic agents that have been identified as biomarkers for disease, and this figure is only likely to increase as research continues in this area.

    Author
    Bioline

    2nd qPCR and Digital PCR Congress 2014, London

    13 September 2014 No comments

    Bioline are pleased to be sponsoring and exhibiting at the 2nd qPCR and Digital PCR Congress in London, England on 20th and 21st October.

    The meeting brings together key opinion leaders from industry and academia, and covers a range of important topics in real-time PCR, including:

    • MIQE guidelines and standardization
    • Quality control of real-time PCR assays
    • Real-time PCR assay design, optimisation and validation
    • Pathogen detection and quantification
    • Sample preparation and quality control
    • Single cell expression analysis
    • Clinical and drug development applications
    • miRNA, ncRNA, siRNA applications
    • Bioinformatics and data analysis

    Case studies in infectious diseases, vaccines, cancer, prenatal diagnosis, diagnostic and clinical applications, microbiology, food microbiology, plant and ecological genomics, as well as other novel applications will be presented.

    A special session at the congress will be devoted to plant breeding, plant genomics and applied food and plant pathogen testing:

    • Plant and ecological genomics
    • Detection and identification of plant pathogens
    • Gene expression analysis
    • Real-time PCR in food research
    • Food safety
    • Genetically modified organism (GMO) quantification in food

    Bioline maintains a significant real-time PCR research and development facility based in London, the heart of the MedCity biocluster for life science, which includes the new Francis Crick Institute. Bioline maintains a significant real-time PCR research and development facility based in London, the heart of the MedCity biocluster for life science, which includes the new Francis Crick Institute.

    See our Your Partner for Plant Research microsite to learn about some of our best tools to enhance your plant research experiments, and download our Plant Research Solutions Guide.

    We will be showcasing our latest real-time PCR technological developments at the congress, including the new SensiFAST cDNA Synthesis Kit, a fast, easy-to-use method of generating the highest quality cDNA for highly accurate real-time PCR results.

    Bioline will also be highlighting our industrial capabilities for custom manufacturing, including enzymes, buffer chemistries, dyes and internal controls for a wide range of applications from plant genotyping, agribiotech, pathogen testing and cancer research, to biomarkers and diagnostics research.

    Our friendly team of real-time PCR specialists will be on-hand at our exhibition booth throughout the event and glad to answer your queries and discuss your research requirements.

    For further details of speakers and topics, please see the Global Engage qPCR & Digital PCR Congress Agenda .

    We look forward to seeing you at the 2014 congress.